Clinical Trials Search Results
- AVS4TL - 0921: Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records of Cancer Patients (Sema4)
Using comprehensive genomic profiling and proteomics to ID underlying genomic drivers of premalignant or malignant conditions in participants in different stages of disease
- BVD-523-ABC: A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (BVD-523-ABC)
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling.
- MCLA-128-CL01: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.
- SER-ISD1-001: A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Adult Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss
Evaluate the feasibility of optimizing the safety & tolerability of serabelisib when combined w/ an ISD with a goal of reducing side effects and enhancing anticancer activity